デフォルト表紙
市場調査レポート
商品コード
1084773

肝炎治療薬の世界市場の規模・シェア・展望・機会の分析 (2022年~2028年):薬剤クラス・疾患タイプ・投与経路・流通チャネル・地域別

Global Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 173 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
肝炎治療薬の世界市場の規模・シェア・展望・機会の分析 (2022年~2028年):薬剤クラス・疾患タイプ・投与経路・流通チャネル・地域別
出版日: 2022年05月10日
発行: Coherent Market Insights
ページ情報: 英文 173 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界的な肝炎の増加が肝炎治療薬市場の成長を後押しすると予想されています。一方で、肝炎治療薬の開発・承認に要する時間の長さなどが予測期間中の市場成長の妨げとなる見通しです。

当レポートでは、世界の肝炎治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、償還シナリオ、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・法規制・動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な展開
  • 規制状況
  • 疫学分析
  • 償還シナリオ
  • PEST分析

第4章 世界の肝炎治療薬市場:薬剤クラス別

  • インターフェロンアルファ
  • HIVNRTI
  • ヌクレオチドポリメラーゼ・NS5A阻害剤の併用療法
  • C型肝炎プロテアーゼ・NS5A阻害剤の併用療法
  • NS5A阻害剤
  • ヌクレオチドポリメラーゼ阻害剤
  • ヌクレオシドアナログ抗ウイルス薬
  • 血小板形成刺激剤

第5章 世界の肝炎治療薬市場:疾患タイプ別

  • B型肝炎
  • C型肝炎
  • その他

第6章 世界の肝炎治療薬市場:投与経路別

  • 経口
  • 注射

第7章 世界の肝炎治療薬市場:流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 世界の肝炎治療薬市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • アフリカ
  • 中東

第9章 競合情勢

  • 企業プロファイル
    • Merck &Co. Inc.
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • LAURUS Labs
    • Zydus Cadila
    • Hetero Healthcare Limited
    • GlaxoSmithKline PLC.
    • Cipla Inc.
  • アナリストの見解

第10章 セクション

目次
Product Code: CMI2977

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.

Market Dynamics

Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.

However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.

Key features of the study:

  • This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hepatitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Hepatitis Drugs Market, By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
  • Global Hepatitis Drugs Market, By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
  • Global Hepatitis Drugs Market, By Route of Administration:
    • Oral
    • Injection
  • Global Hepatitis Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hepatitis Drugs Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Hepatitis B NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Merck & Co. Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • LAURUS Labs
    • Zydus Cadila
    • Hetero Healthcare Limited
    • GlaxoSmithKline PLC
    • Cipla Inc.

"*" marked represents similar segmentation in other categories in the respective section

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Landscape
  • Epidemiology Analysis
  • Reimbursement Scenario
  • PEST Analysis

4. Global Hepatitis Drugs Market, By Drug Class, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Interferon Alphas
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • HIV NRTIs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Hepatitis C Protease / NS5A Inhibitor Combinations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • NS5A Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nucleotide Polymerase Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nucleoside Analogue Antivirals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Thrombopoiesis Stimulating Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Hepatitis Drugs Market, By Disease Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hepatitis B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Hepatitis C
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Hepatitis Drugs Market, By Route of Administration, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Hepatitis Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Hepatitis Drugs Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028(%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)l
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

9. Competitive Landscape

  • Company Profiles
    • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Gilead Sciences Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • LAURUS Labs
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Zydus Cadila
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Hetero Healthcare Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline PLC.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Cipla Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact